Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Long-Term Debt Issuances (2020 - 2024)

ImmunityBio (IBRX) has disclosed Long-Term Debt Issuances for 5 consecutive years, with -$97.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Long-Term Debt Issuances fell 137.48% to -$97.0 million in Q4 2024 year-over-year; TTM through Dec 2025 was -$97.0 million, a N/A change, with the full-year FY2023 number at $258.7 million, up 48.57% from a year prior.
  • Long-Term Debt Issuances was -$97.0 million for Q4 2024 at ImmunityBio, down from $97.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $298.5 million in Q4 2021 to a low of -$97.0 million in Q4 2024.
  • A 5-year average of $80.5 million and a median of $56.7 million in 2020 define the central range for Long-Term Debt Issuances.
  • Biggest YoY gain for Long-Term Debt Issuances was 420.0% in 2023; the steepest drop was 148.0% in 2023.
  • ImmunityBio's Long-Term Debt Issuances stood at $63.7 million in 2020, then skyrocketed by 368.6% to $298.5 million in 2021, then tumbled by 83.33% to $49.8 million in 2022, then soared by 420.0% to $258.7 million in 2023, then tumbled by 137.48% to -$97.0 million in 2024.
  • Per Business Quant, the three most recent readings for IBRX's Long-Term Debt Issuances are -$97.0 million (Q4 2024), $97.0 million (Q2 2024), and $258.7 million (Q4 2023).